Plasma cell–directed therapy for rituximab-refractory PLA2R+ membranous nephropathy

Journal Article Corrected proof Plasma cell–directed therapy for rituximab-refractory PLA2R+ membranous nephropathy Get access Sofiane Salhi, Sofiane Salhi Department of Organ Transplantation, National Reference Centre for Rare Kidney Diseases – SORARE, University Hospital of Toulouse, Toulouse, France Search for other works by this author on: Oxford Academic PubMed Google Scholar David Ribes, David Ribes Department of Organ Transplantation, National Reference Centre for Rare Kidney Diseases – SORARE, University Hospital of Toulouse, Toulouse, France Search for other works by this author on: Oxford Academic PubMed Google Scholar Françoise Fortenfant, Françoise Fortenfant Laboratory of Immunology, University Hospital of Toulouse, Toulouse, France Search for other works by this author on: Oxford Academic PubMed Google Scholar Stanislas Faguer Stanislas Faguer Department of Organ Transplantation, National Reference Centre for Rare Kidney Diseases – SORARE, University Hospital of Toulouse, Toulouse, FranceUniversity Paul Sabatier – Toulouse 3, Faculty of Medicine, Toulouse, FranceINSERM UMR 1297, Institute of Metabolic and Cardiovascular Diseases, Team ‘Kidney Diseases: biomarkers, prevention and treatment’, Toulouse, France Correspondence to: Stanislas Faguer; E-mail: stanislas.faguer@inserm.fr; Twitter handle: #Faguer_S Search for other works by this author on: Oxford Academic PubMed Google Scholar Nephrology Dialysis Transplantation, gfad135, https://doi.org/10.1093/ndt/gfad135 Published: 03 July 2023 Article history Received: 20 April 2023 Published: 03 July 2023 Corrected and typeset: 13 July 2023